Upstream Bio (UPB) Receivables (2023 - 2026)

Upstream Bio's Receivables history runs 4 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Receivables rose 50.0% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 50.0% YoY), while the FY2025 annual figure was $2.3 million, up 96.69% from the prior year.
• Receivables was $2.6 million for Q1 2026 at Upstream Bio, up from $2.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.6 million in Q2 2025 to a low of $236000.0 in Q4 2023.
• Historically, Receivables has averaged $1.6 million across 4 years, with a median of $1.7 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Receivables soared 400.0% in 2024, then jumped 50.0% in 2026.
• A 4-year view of Receivables shows it stood at $236000.0 in 2023, then jumped by 400.0% to $1.2 million in 2024, then soared by 96.69% to $2.3 million in 2025, then advanced by 12.32% to $2.6 million in 2026.
• The last three Receivables figures came in at $2.6 million (Q1 2026), $2.3 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.